Results of a Phase 1, Dose-finding Study of Debio 0123 as Monotherapy in Adult Patients with Advanced Solid Tumors – Safety, Pharmacokinetic, and Preliminary Antitumor Activity Data

Poster presented at ASCO 2024

Kyriakos P. Papadopoulos,¹ Manish R. Sharma,² Reinhard Dummer,³ Ilaria Colombo,⁴ Egle Ramelyte,³ Leigh Seamon,² Drew W. Rasco,¹ Victor Rodriguez-Freixinos,⁵ Vito Dozio,⁵ Tri Tat,⁵ Noemie Luong,⁵ Aliaksandr Hurynovich,⁵ Mokhtar Omar,⁵ Sandrine Micallef,⁵ Anne Bellon,⁵ Esteban Rodrigo Imedio,⁵ Anastasios Stathis⁴

¹START San Antonio, San Antonio, TX
²START Midwest, Grand Rapids, MI
³Department of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
⁴Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland
⁵Debiopharm International SA, Lausanne, Switzerland